scispace - formally typeset
Journal ArticleDOI

Comparison of three different preparations of platelet concentrates for growth factor enrichment

Reads0
Chats0
TLDR
The two systems for intraoperative use are similar in their effects on the platelets; the highest concentration of platelets per micro L is gained with the Curasan system; the laboratory system may offer an alternative if an intraoperative system is not available.
Abstract
The aim of the present study was to compare three different systems for preparing platelet concentrates: two commercially available bed-side techniques (Curasan system and PCCS) and a procedure used routinely in transfusion medicine. Platelet concentrates were prepared from venous blood of 12 healthy male volunteers using the three different systems. Platelet and leucocyte counts were performed and platelet derived growth factor and transforming growth factor beta were assayed by enzyme linked immunoassay. Handling was also considered. The three systems were able to collect 19.0 ± 16.6% (laboratory system), 41.9 ± 9.7% (Curasan system) and 49.6 ± 21.0% (PCCS) of the absolute number of platelets which were originally in the venous blood volume within the platelet concentrate. Due to the amount of plasma which is left in the platelet concentrate portion, the platelet concentration could be increased between 1.4 ± 1.3 times (laboratory system), 5.0 ± 2.3 times (PCCS) and 11.7 ± 2.4 times (Curasan system) compared to the venous blood. The amount of growth factors correlated with the number of platelets within the platelet concentrates. The two systems for intraoperative use are similar in their effects on the platelets. The absolute gain of platelets seems to be the highest with the PCCS; the highest concentration of platelets per µL is gained with the Curasan system. The laboratory system may offer an alternative if an intraoperative system is not available.

read more

Citations
More filters
Journal ArticleDOI

Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features.

TL;DR: Initial analyses revealed that slow fibrin polymerization during PRF processing leads to the intrinsic incorporation of platelet cytokines and glycanic chains in the fibrIn meshes, which would imply that PRF, unlike the other platelet concentrates, would be able to progressively release cytokines during fibr in matrix remodeling; such a mechanism might explain the clinically observed healing properties of PRF.
Journal ArticleDOI

Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates?

TL;DR: Initial analyses revealed that PRF could be an immune regulation node with inflammation retrocontrol abilities, which could explain the reduction of postoperative infections when PRF is used as surgical additive.
Journal ArticleDOI

Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies.

TL;DR: Choukroun's platelet-rich fibrin (PRF) is a second generation platelet concentrate that releases high quantities of three main growth factors, including TGFβ-1, platelet derived growth factor AB, PDGF-AB and an important coagulation matricellular glycoprotein during 7 days.
Journal ArticleDOI

Platelet-Rich Plasma: Growth Factors and Pro- and Anti-Inflammatory Properties

TL;DR: PRP is a rich source of growth factors and promoted significant changes in monocyte-mediated proinflammatory cytokine/chemokine release and lipoxin A(4) (LXA(4)) generation, suggesting that PRP may suppress cytokine release, limit inflammation, and, thereby, promote tissue regeneration.
Journal ArticleDOI

Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons

TL;DR: The findings of this study support in vivo investigation of PRP as an autogenous, patient‐side treatment for tendonitis as well as other blood products tested.
References
More filters
Journal ArticleDOI

Platelet-rich plasma: Growth factor enhancement for bone grafts

TL;DR: Monoclonal antibody assessment of cancellous cellular marrow grafts demonstrated cells that were capable of responding to the growth factors by bearing cell membrane receptors and evidenced a radiographic maturation rate 1.62 to 2.16 times that of grafts without platelet-rich plasma.
Journal ArticleDOI

The biology of platelet-derived growth factor

TL;DR: The biology of platelet derived growth factor, it will really give you the good idea to be successful.
Journal Article

Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants.

TL;DR: Preliminary clinical evidence is presented of the beneficial effect of the use of plasma rich in growth factors of autologous origin, which can introduce several advantages, including the enhancement and acceleration of bone regeneration and more rapid and predictable soft tissue healing.
Journal ArticleDOI

The effects of short-term application of a combination of platelet-derived and insulin-like growth factors on periodontal wound healing.

TL;DR: The combination of PDGF and IGF-I may enhance regeneration of both the soft and hard tissue components of the periodontium as discussed by the authors, however, the results showed that the regeneration of new bone and cementum did not change significantly from 2 to 5 weeks.
Journal ArticleDOI

Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation.

TL;DR: Use of ITA for gel preparation is equivalent to using calcium chloride and thrombin, without the need for special equipment and the risk of coagulopathy.
Related Papers (5)
Trending Questions (1)
Which Millet is good for platelets?

The two systems for intraoperative use are similar in their effects on the platelets.